Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs Primary Clinic (Direct GLP)

Two GLP-1 desks, one scoreboard. We put Trimi and Primary Clinic (Direct GLP) head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 186 · Grade C

Primary Clinic (Direct GLP)

Visit Primary Clinic (Direct GLP) Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 67 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Primary Clinic (Direct GLP) a bad call — it's best for readers who want glp-1 at wholesale cost inside a direct primary care membership. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
48
Supply Reliability
89
69
Transparency
91
88
Access Breadth
89
64
Clinical Oversight
88
77
Track Record
84
57
TrimiBrief Score 89 · 67Primary Clinic (Direct GLP)

Price, coverage & the tracker

TrimiPrimary Clinic (Direct GLP)
Brief Score89/100 (B+)67/100 (C)
Semaglutide$196/moFrom $65/mo (0.25 mg dose, compounded)
Tirzepatide$296/moFrom $110/mo (2.5 mg dose, compounded)
CoverageAll 50 states10 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Primary Clinic (Direct GLP): New to the tracker on 1 August 2026. The published line reads From $65/mo (0.25 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.